Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.

Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM.

Neuropsychopharmacology. 2019 Jan 26. doi: 10.1038/s41386-019-0324-9. [Epub ahead of print]

PMID:
30685771
2.

DMT Models the Near-Death Experience.

Timmermann C, Roseman L, Williams L, Erritzoe D, Martial C, Cassol H, Laureys S, Nutt D, Carhart-Harris R.

Front Psychol. 2018 Aug 15;9:1424. doi: 10.3389/fpsyg.2018.01424. eCollection 2018.

3.

Effects of psilocybin therapy on personality structure.

Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, Carhart-Harris RL.

Acta Psychiatr Scand. 2018 Nov;138(5):368-378. doi: 10.1111/acps.12904. Epub 2018 Jun 19.

4.

Are ecstasy induced serotonergic alterations overestimated for the majority of users?

Szigeti B, Winstock AR, Erritzoe D, Maier LJ.

J Psychopharmacol. 2018 Jul;32(7):741-748. doi: 10.1177/0269881118767646. Epub 2018 May 7.

PMID:
29733742
5.

Psychedelics and the essential importance of context.

Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, Kaelen M.

J Psychopharmacol. 2018 Jul;32(7):725-731. doi: 10.1177/0269881118754710. Epub 2018 Feb 15.

PMID:
29446697
6.

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ.

Psychopharmacology (Berl). 2018 Feb;235(2):399-408. doi: 10.1007/s00213-017-4771-x. Epub 2017 Nov 8.

7.

Psychedelics and connectedness.

Carhart-Harris RL, Erritzoe D, Haijen E, Kaelen M, Watts R.

Psychopharmacology (Berl). 2018 Feb;235(2):547-550. doi: 10.1007/s00213-017-4701-y. Epub 2017 Aug 10.

PMID:
28795211
8.

Lessons to be learned from early psychedelic therapy in Denmark.

Erritzoe D, Richards WA.

Nord J Psychiatry. 2017 Oct;71(7):487-488. doi: 10.1080/08039488.2017.1336252. Epub 2017 Jul 20. No abstract available.

PMID:
28727504
9.

Concerns regarding conclusions made about LSD-treatments (received 25 October 2016).

Erritzoe D, Nutt DJ, Carhart-Harris R.

Hist Psychiatry. 2017 Jun;28(2):257-260. doi: 10.1177/0957154X17692197. Epub 2017 Feb 15. No abstract available.

PMID:
28198192
10.

Altered Insula Connectivity under MDMA.

Walpola IC, Nest T, Roseman L, Erritzoe D, Feilding A, Nutt DJ, Carhart-Harris RL.

Neuropsychopharmacology. 2017 Oct;42(11):2152-2162. doi: 10.1038/npp.2017.35. Epub 2017 Feb 14.

11.

Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [11C]PBR28 PET study.

Kalk NJ, Guo Q, Owen D, Cherian R, Erritzoe D, Gilmour A, Ribeiro AS, McGonigle J, Waldman A, Matthews P, Cavanagh J, McInnes I, Dar K, Gunn R, Rabiner EA, Lingford-Hughes AR.

Transl Psychiatry. 2017 Jan 10;7(1):e996. doi: 10.1038/tp.2016.264.

12.

Neural substrates of cue reactivity and craving in gambling disorder.

Limbrick-Oldfield EH, Mick I, Cocks RE, McGonigle J, Sharman SP, Goldstone AP, Stokes PR, Waldman A, Erritzoe D, Bowden-Jones H, Nutt D, Lingford-Hughes A, Clark L.

Transl Psychiatry. 2017 Jan 3;7(1):e992. doi: 10.1038/tp.2016.256.

13.

Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity.

Mick I, Ramos AC, Myers J, Stokes PR, Chandrasekera S, Erritzoe D, Mendez MA, Gunn RN, Rabiner EA, Searle GE, Galduróz JCF, Waldman AD, Bowden-Jones H, Clark L, Nutt DJ, Lingford-Hughes AR.

Addict Biol. 2017 Nov;22(6):1601-1609. doi: 10.1111/adb.12457. Epub 2016 Oct 13.

14.

Serotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy use.

Laursen HR, Henningsson S, Macoveanu J, Jernigan TL, Siebner HR, Holst KK, Skimminge A, Knudsen GM, Ramsoy TZ, Erritzoe D.

J Psychopharmacol. 2016 Dec;30(12):1296-1304. Epub 2016 Sep 5.

15.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ.

Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7. Epub 2016 May 17.

16.

Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers.

Mick I, Myers J, Ramos AC, Stokes PR, Erritzoe D, Colasanti A, Gunn RN, Rabiner EA, Searle GE, Waldman AD, Parkin MC, Brailsford AD, Galduróz JC, Bowden-Jones H, Clark L, Nutt DJ, Lingford-Hughes AR.

Neuropsychopharmacology. 2016 Jun;41(7):1742-50. doi: 10.1038/npp.2015.340. Epub 2015 Nov 10.

17.

The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.

Paterson LM, Flechais RS, Murphy A, Reed LJ, Abbott S, Boyapati V, Elliott R, Erritzoe D, Ersche KD, Faluyi Y, Faravelli L, Fernandez-Egea E, Kalk NJ, Kuchibatla SS, McGonigle J, Metastasio A, Mick I, Nestor L, Orban C, Passetti F, Rabiner EA, Smith DG, Suckling J, Tait R, Taylor EM, Waldman AD, Robbins TW, Deakin JF, Nutt DJ, Lingford-Hughes AR; ICCAM Platform.

J Psychopharmacol. 2015 Sep;29(9):943-60. doi: 10.1177/0269881115596155. Epub 2015 Aug 5.

18.

The Center for Integrated Molecular Brain Imaging (Cimbi) database.

Knudsen GM, Jensen PS, Erritzoe D, Baaré WF, Ettrup A, Fisher PM, Gillings N, Hansen HD, Hansen LK, Hasselbalch SG, Henningsson S, Herth MM, Holst KK, Iversen P, Kessing LV, Macoveanu J, Madsen KS, Mortensen EL, Nielsen FÅ, Paulson OB, Siebner HR, Stenbæk DS, Svarer C, Jernigan TL, Strother SC, Frokjaer VG.

Neuroimage. 2016 Jan 1;124(Pt B):1213-9. doi: 10.1016/j.neuroimage.2015.04.025. Epub 2015 Apr 17.

19.

The dopamine theory of addiction: 40 years of highs and lows.

Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR.

Nat Rev Neurosci. 2015 May;16(5):305-12. doi: 10.1038/nrn3939. Epub 2015 Apr 15. Review.

PMID:
25873042
20.

Acute increases in synaptic GABA detectable in the living human brain: a [¹¹C]Ro15-4513 PET study.

Stokes PR, Myers JF, Kalk NJ, Watson BJ, Erritzoe D, Wilson SJ, Cunningham VJ, Riano Barros D, Hammers A, Turkheimer FE, Nutt DJ, Lingford-Hughes AR.

Neuroimage. 2014 Oct 1;99:158-65. doi: 10.1016/j.neuroimage.2014.05.035. Epub 2014 May 17.

PMID:
24844747
21.

Amphetamine induced endogenous opioid release in the human brain detected with [¹¹C]carfentanil PET: replication in an independent cohort.

Mick I, Myers J, Stokes PR, Erritzoe D, Colasanti A, Bowden-Jones H, Clark L, Gunn RN, Rabiner EA, Searle GE, Waldman AD, Parkin MC, Brailsford AD, Nutt DJ, Lingford-Hughes AR.

Int J Neuropsychopharmacol. 2014 Dec;17(12):2069-74. doi: 10.1017/S1461145714000704. Epub 2014 May 7.

PMID:
24807268
22.

In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users.

Frokjaer VG, Erritzoe D, Holst KK, Madsen KS, Fisher PM, Madsen J, Svarer C, Knudsen GM.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1119-28. doi: 10.1017/S1461145714000066. Epub 2014 Feb 14.

PMID:
24524290
23.

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity.

Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, Ferguson B, Williams LT, Roseman L, Brugger S, De Meer I, Tanner M, Tyacke R, Wolff K, Sethi A, Bloomfield MA, Williams TM, Bolstridge M, Stewart L, Morgan C, Newbould RD, Feilding A, Curran HV, Nutt DJ.

Biol Psychiatry. 2015 Oct 15;78(8):554-62. doi: 10.1016/j.biopsych.2013.12.015. Epub 2014 Jan 10.

24.

In vivo imaging of cerebral dopamine D3 receptors in alcoholism.

Erritzoe D, Tziortzi A, Bargiela D, Colasanti A, Searle GE, Gunn RN, Beaver JD, Waldman A, Nutt DJ, Bani M, Merlo-Pich E, Rabiner EA, Lingford-Hughes A.

Neuropsychopharmacology. 2014 Jun;39(7):1703-12. doi: 10.1038/npp.2014.18. Epub 2014 Jan 28.

25.

The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories.

Carhart-Harris RL, Wall MB, Erritzoe D, Kaelen M, Ferguson B, De Meer I, Tanner M, Bloomfield M, Williams TM, Bolstridge M, Stewart L, Morgan CJ, Newbould RD, Feilding A, Curran HV, Nutt DJ.

Int J Neuropsychopharmacol. 2014 Apr;17(4):527-40. doi: 10.1017/S1461145713001405. Epub 2013 Dec 17.

PMID:
24345398
26.

Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients.

Orban C, McGonigle J, Kalk NJ, Erritzoe D, Waldman AD, Nutt DJ, Rabiner EA, Lingford-Hughes AR.

Am J Drug Alcohol Abuse. 2013 Nov;39(6):433-40. doi: 10.3109/00952990.2013.846348.

PMID:
24200213
27.

Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition.

Macoveanu J, Hornboll B, Elliott R, Erritzoe D, Paulson OB, Siebner H, Knudsen GM, Rowe JB.

Neuropsychopharmacology. 2013 May;38(6):996-1005. doi: 10.1038/npp.2012.264. Epub 2012 Dec 19.

28.

History of cigarette smoking is associated with higher limbic GABAA receptor availability.

Stokes PR, Benecke A, Myers J, Erritzoe D, Watson BJ, Kalk N, Barros DR, Hammers A, Nutt DJ, Lingford-Hughes AR.

Neuroimage. 2013 Apr 1;69:70-7. doi: 10.1016/j.neuroimage.2012.12.010. Epub 2012 Dec 14.

PMID:
23247185
29.

Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.

Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ.

Schizophr Bull. 2013 Nov;39(6):1343-51. doi: 10.1093/schbul/sbs117. Epub 2012 Oct 8.

30.

Influence of different cellular environments on [(3)H]DASB radioligand binding.

Quelch DR, Parker CA, Nutt DJ, Tyacke RJ, Erritzoe D.

Synapse. 2012 Dec;66(12):1035-9. doi: 10.1002/syn.21605. Epub 2012 Sep 20. No abstract available.

PMID:
22927261
31.

Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response.

Frokjaer VG, Erritzoe D, Holst KK, Jensen PS, Rasmussen PM, Fisher PM, Baaré W, Madsen KS, Madsen J, Svarer C, Knudsen GM.

Eur Neuropsychopharmacol. 2013 Apr;23(4):285-94. doi: 10.1016/j.euroneuro.2012.05.013. Epub 2012 Jun 23.

PMID:
22732516
32.

Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.

Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, Erritzoe D.

Hum Psychopharmacol. 2012 Jul;27(4):352-63. doi: 10.1002/hup.2234. Epub 2012 Jun 14.

PMID:
22696164
33.

The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study.

Mendez MA, Horder J, Myers J, Coghlan S, Stokes P, Erritzoe D, Howes O, Lingford-Hughes A, Murphy D, Nutt D.

Neuropharmacology. 2013 May;68:195-201. doi: 10.1016/j.neuropharm.2012.04.008. Epub 2012 Apr 21.

34.

Endogenous opioid release in the human brain reward system induced by acute amphetamine administration.

Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA.

Biol Psychiatry. 2012 Sep 1;72(5):371-7. doi: 10.1016/j.biopsych.2012.01.027. Epub 2012 Mar 3.

PMID:
22386378
35.

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ.

Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43. doi: 10.1073/pnas.1119598109. Epub 2012 Jan 23.

36.

Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.

Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ.

Br J Psychiatry. 2012 Mar;200(3):238-44. doi: 10.1192/bjp.bp.111.103309. Epub 2012 Jan 26.

PMID:
22282432
37.

Fluid and white matter suppression with the MP2RAGE sequence.

Tanner M, Gambarota G, Kober T, Krueger G, Erritzoe D, Marques JP, Newbould R.

J Magn Reson Imaging. 2012 May;35(5):1063-70. doi: 10.1002/jmri.23532. Epub 2011 Dec 14.

PMID:
22170818
38.

In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.

Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, Madsen J, Rasmussen PM, Ramsøy T, Jernigan TL, Knudsen GM.

Arch Gen Psychiatry. 2011 Jun;68(6):562-76. doi: 10.1001/archgenpsychiatry.2011.56.

39.

Serotonin transporter binding in the hypothalamus correlates negatively with tonic heat pain ratings in healthy subjects: a [11C]DASB PET study.

Kupers R, Frokjaer VG, Erritzoe D, Naert A, Budtz-Joergensen E, Nielsen FA, Kehlet H, Knudsen GM.

Neuroimage. 2011 Jan 15;54(2):1336-43. doi: 10.1016/j.neuroimage.2010.09.010. Epub 2010 Sep 19.

PMID:
20851771
40.

Cerebral 5-HT2A receptor and serotonin transporter binding in humans are not affected by the val66met BDNF polymorphism status or blood BDNF levels.

Klein AB, Trajkovska V, Erritzoe D, Haugbol S, Madsen J, Baaré W, Aznar S, Knudsen GM.

J Cereb Blood Flow Metab. 2010 Nov;30(11):e1-7. doi: 10.1038/jcbfm.2010.114. Epub 2010 Aug 25.

41.

Cognitive function is related to fronto-striatal serotonin transporter levels--a brain PET study in young healthy subjects.

Madsen K, Erritzoe D, Mortensen EL, Gade A, Madsen J, Baaré W, Knudsen GM, Hasselbalch SG.

Psychopharmacology (Berl). 2011 Feb;213(2-3):573-81. doi: 10.1007/s00213-010-1926-4. Epub 2010 Jul 10.

PMID:
20623110
42.

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.

Rasmussen H, Ebdrup BH, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, Pinborg LH, Baaré WF, Svarer C, Lublin H, Knudsen GM, Glenthoj B.

Psychopharmacology (Berl). 2011 Feb;213(2-3):583-92. doi: 10.1007/s00213-010-1941-5. Epub 2010 Jul 8.

PMID:
20614105
43.

Cerebral serotonin transporter binding is inversely related to body mass index.

Erritzoe D, Frokjaer VG, Haahr MT, Kalbitzer J, Svarer C, Holst KK, Hansen DL, Jernigan TL, Lehel S, Knudsen GM.

Neuroimage. 2010 Aug 1;52(1):284-9. doi: 10.1016/j.neuroimage.2010.03.086. Epub 2010 Apr 9.

44.

Endogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor binding.

Frokjaer VG, Erritzoe D, Juul A, Nielsen FA, Holst K, Svarer C, Madsen J, Paulson OB, Knudsen GM.

Psychoneuroendocrinology. 2010 Oct;35(9):1311-20. doi: 10.1016/j.psyneuen.2010.03.002. Epub 2010 Mar 30.

PMID:
20356681
45.

A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: an in vivo molecular imaging study in humans.

Erritzoe D, Holst K, Frokjaer VG, Licht CL, Kalbitzer J, Nielsen FA, Svarer C, Madsen J, Knudsen G.

J Neurosci. 2010 Mar 3;30(9):3391-7. doi: 10.1523/JNEUROSCI.2852-09.2010.

46.

Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes.

Kalbitzer J, Erritzoe D, Holst KK, Nielsen FA, Marner L, Lehel S, Arentzen T, Jernigan TL, Knudsen GM.

Biol Psychiatry. 2010 Jun 1;67(11):1033-9. doi: 10.1016/j.biopsych.2009.11.027. Epub 2010 Jan 27.

PMID:
20110086
47.

Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET.

Marner L, Gillings N, Madsen K, Erritzoe D, Baaré WF, Svarer C, Hasselbalch SG, Knudsen GM.

Neuroimage. 2010 Apr 15;50(3):855-61. doi: 10.1016/j.neuroimage.2010.01.054. Epub 2010 Jan 22.

PMID:
20096787
48.

Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia.

Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, Kalbitzer J, Madsen J, Pinborg LH, Baaré W, Svarer C, Lublin H, Knudsen GM, Glenthoj B.

Arch Gen Psychiatry. 2010 Jan;67(1):9-16. doi: 10.1001/archgenpsychiatry.2009.176.

PMID:
20048218
49.

Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding.

Frokjaer VG, Vinberg M, Erritzoe D, Baaré W, Holst KK, Mortensen EL, Arfan H, Madsen J, Jernigan TL, Kessing LV, Knudsen GM.

Neuropsychopharmacology. 2010 Apr;35(5):1129-37. doi: 10.1038/npp.2009.218. Epub 2009 Dec 30.

50.

Gender and the use of hormonal contraception in women are not associated with cerebral cortical 5-HT 2A receptor binding.

Frokjaer VG, Erritzoe D, Madsen J, Paulson OB, Knudsen GM.

Neuroscience. 2009 Oct 6;163(2):640-5. doi: 10.1016/j.neuroscience.2009.06.052. Epub 2009 Jun 25.

PMID:
19559762

Supplemental Content

Loading ...
Support Center